Rituximab Biosimilars Produce Big Cost Savings, are Effective

September 07, 2021

A large Netherlands study demonstrated that rituximab biosimilars (R-biosimilars) produced a 43 percent reduction in annual costs. In addition, three-year overall survival did not differ between diffuse large B-cell lymphoma (DLBCL) and those receiving rituximab, according to the researchers.

The Generic, Biosimilar Medicine Industry Today and What it Can Become in The Next Decade

July 14, 2021

International Generic and Biosimilar Medicines Association recently released the report, "A Vision for the Global Generic and Biosimilar Medicines Industry,” covering the current global Generic and Biosimilar medicine industry, and released a vision of what the market will be in 2030 and how to achieve it.

Generic Drug Price Tags: Too High. And Too Low. Competition Can Help Create an In-Between.

July 13, 2021

Low prices and some gaming of regulations can drive out competitors and create monopolies that allow generic makers to jack up their prices. Experience has shown that it often takes multiple generics to achieve the promised-for downward pressure on prices.

Biden Executive Order Takes Aim at Drug Prices, Hospital Mergers

July 09, 2021

Hospital mergers, drug prices, and non-compete clauses for the rank and file are all targets of President Joe Biden’s pen today as he signed a sweeping executive order instructing federal departments and agencies to reshape what he called “booming” economy by putting workers first, encouraging higher wages and the opportunity for mobility.